Identification of BXDC2 as a Key Downstream Effector of the Androgen Receptor in Modulating Cisplatin Sensitivity in Bladder Cancer

SIMPLE SUMMARY: It remains unclear why chemotherapy is often ineffective in patients with bladder cancer. Meanwhile, we previously reported that male sex hormones (i.e., androgens) could considerably reduce the efficacy of cisplatin, an anti-cancer drug used as the first-line treatment against advan...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Guiyang, Teramoto, Yuki, Goto, Takuro, Mizushima, Taichi, Inoue, Satoshi, Ide, Hiroki, Nagata, Yujiro, Kashiwagi, Eiji, Baras, Alexander S., Netto, George J., Yang, Zhiming, Miyamoto, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7956795/
https://www.ncbi.nlm.nih.gov/pubmed/33652650
http://dx.doi.org/10.3390/cancers13050975

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7956795/
https://www.ncbi.nlm.nih.gov/pubmed/33652650
http://dx.doi.org/10.3390/cancers13050975

Ejemplares similares